The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

Cancer treatment and research

Volumn 103, Issue , 2000, Pages 57-75

  Pegram, M D ^a   Konecny, G ^a   Slamon, D J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH PROMOTOR; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR PROTEIN;

ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DESIGN; DRUG INTERACTION; FEMALE; FORECASTING; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; METASTASIS; MOUSE; MULTIMODALITY CANCER THERAPY; PASSIVE IMMUNIZATION; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DRUG DESIGN; DRUG INTERACTIONS; FEMALE; FORECASTING; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GROWTH SUBSTANCES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FC FRAGMENTS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2;

MLCS; MLOWN;

EID: 0033651234     PISSN: 09273042     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-1-4757-3147-7_4     Document Type: Review

References (42)